Skip to main content
. 2021 Dec 2;28(5):903–914. doi: 10.1158/1078-0432.CCR-21-2547

Figure 3.

Figure 3. Leukocyte infiltration at baseline and after 43 days on treatment. A, The percentage of total nucleated cells that were CD45+ (total leukocytes) are shown for each patient at baseline and after 43 days of treatment (Rx). Green lines pairing baseline and Rx samples reflect a >10% increase in ratio after treatment compared with baseline. Leukocyte lineage subtypes are shown as the percentages of total CD45+ cells per patient at baseline (B) and after 43 days of treatment (C). Pembrolizumab monotherapy, n = 5; pembrolizumab plus acalabrutinib combination therapy, n = 4 at baseline and n = 2 with treatment at day 43. Colors delineate cell types as indicated in the legend (right of B and C). In B and C, human papillomavirus (HPV) status was evaluated by p16-positivity via a multiplex immunohistochemical platform, and used as a molecular correlate for HPV status, where results are denoted as “+” and “−” for HPV-positive and HPV-negative, respectively.

Leukocyte infiltration at baseline and after 43 days on treatment. A, The percentage of total nucleated cells that were CD45+ (total leukocytes) are shown for each patient at baseline and after 43 days of treatment (Rx). Green lines pairing baseline and Rx samples reflect a >10% increase in ratio after treatment compared with baseline. Leukocyte lineage subtypes are shown as the percentages of total CD45+ cells per patient at baseline (B) and after 43 days of treatment (C). Pembrolizumab monotherapy, n = 5; pembrolizumab plus acalabrutinib combination therapy, n = 4 at baseline and n = 2 with treatment at day 43. Colors delineate cell types as indicated in the legend (right of B and C). In B and C, human papillomavirus (HPV) status was evaluated by p16-positivity via a multiplex immunohistochemical platform, and used as a molecular correlate for HPV status, where results are denoted as “+” and “−” for HPV-positive and HPV-negative, respectively.